Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi

European Respiratory Journal

Volumn 29, Issue 3, 2007, Pages 575-581

  Naline, E ^a   Trifilieff, A ^c   Fairhurst, R A ^c   Advenier, C ^a   Molimard, Mathieu ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

2 adrenoceptor agonists; Airways smooth muscle; Formoterol; Indacaterol; Isolated human bronchus; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE; INDACATEROL; ISOPRENALINE; MONTELUKAST; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; ARTICLE; BRONCHUS MUSCLE; CHOLINERGIC STIMULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ELECTROSTIMULATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; LUNG SURGERY; MALE; MUSCLE CONTRACTION; MUSCLE EXCITATION; MUSCLE RELAXATION; MUSCLE TONE; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; AIRWAY RESISTANCE; ALBUTEROL; BRONCHI; BRONCHOCONSTRICTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ETHANOLAMINES; FEMALE; HUMANS; INDANS; ISOPROTERENOL; MALE; MIDDLE AGED; MUSCLE, SMOOTH; QUINOLONES; TREATMENT OUTCOME;

EID: 33847724812     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00032806     Document Type: Article

References (27)

1. Kips JC, Pauwels RA. Long-acting inhaled N-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164: 923-932.
2. 2-adrenoceptor agonists in asthma management. Respir Med 2005; 99: 152-170.
3. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
4. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) Intemational Study Group. N Engl J Med 1997; 337: 1405-1411.
5. Wookock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
6. 2-agonists and corticosteroids in stable COPD. Chest 2004; 126: 220-237.
7. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001; 46: 798-825.
8. Rabe KF, Jorres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
9. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684-1688.
10. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir 11994; 7: 914-920.
11. Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102: 535-538.
12. 2-adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998; 11: 583-588.
13. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002; 165: 1353-1358.
14. 2-adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762-770.
15. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2006; [Epub ahead of print PMID: 17088091].
16. Sarria B, Naline E, Cortijo J, et al. Functional, biochemical and morphological studies on human bronchi after cryopreservation. Br J Pharmacol 1995; 116: 2569-2574.
17. Naline E, Qian Y, Advenier C, Raebum D, Karlsson JA. Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br j Pharmacol 1996; 118: 1939-1944.
18. Watson N, Magnussen H, Rabe KF. The relevance of resting tension to responsiveness and inherent tone of human bronchial smooth muscle. Br J Pharmacol 1998; 123: 694-700.
19. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150: 1640-1645.
20. Van Amsterdam RG, Meurs H, Ten Berge RE, Veninga NC, Brouwer F, Zaagsma J. Role of phosphoinositide metabolism in human bronchial smooth muscle contraction and in functional antagonism by 13-adrenoceptor agonists. Am Rev Respir Dis 1990; 142: 1124-1128.
21. Bames PJ. β-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838-860.
22. Sarria B, Naline E, Zhang Y, et al. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1125-L1132.
23. Linden A, Bergendal A, Ullman A, Skoogh BE, Lofdahl CG. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.
24. Rabe KF, Giembycz MA, Dent G, Perkins RS, Evans P, Bames PJ. Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993; 231: 305-308.
25. Anderson GP, Linden A, Rabe KF. Why are long-acting β-adrenoceptor agonists long-acting? Eur Respir J 1994; 7: 569-578.
26. Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, Vardey CJ. Effects of β-adrenoceptor agonists in human bronchial smooth muscle. Br j Pharmacol 1993; 110: 1112-1116.
27. Nials AT, Ball DI, Butchers PR, et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127-135.